ANI Pharmaceuticals (NASDAQ:ANIP) Updates FY 2026 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided EPS guidance of 9.190-9.690 for the period, compared to the consensus EPS estimate of 8.790. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

ANI Pharmaceuticals Stock Down 2.4%

Shares of ANIP opened at $81.86 on Friday. ANI Pharmaceuticals has a 12 month low of $56.71 and a 12 month high of $99.50. The firm’s 50 day moving average is $76.82 and its 200-day moving average is $81.01. The stock has a market capitalization of $1.83 billion, a PE ratio of 24.36 and a beta of 0.46. The company has a current ratio of 2.71, a quick ratio of 2.19 and a debt-to-equity ratio of 1.11.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 8.87% and a return on equity of 27.97%. The company had revenue of $237.46 million for the quarter, compared to analysts’ expectations of $207.63 million. During the same period last year, the firm earned $1.70 earnings per share. The business’s revenue for the quarter was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities research analysts forecast that ANI Pharmaceuticals will post 7.64 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on ANIP shares. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. Zacks Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 15th. Finally, Guggenheim raised their target price on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a report on Friday, January 16th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $107.33.

Insiders Place Their Bets

In related news, SVP Krista Davis sold 2,084 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $77.53, for a total value of $161,572.52. Following the transaction, the senior vice president directly owned 50,993 shares of the company’s stock, valued at $3,953,487.29. This trade represents a 3.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Ori Gutwerg sold 2,060 shares of ANI Pharmaceuticals stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $76.50, for a total transaction of $157,590.00. Following the completion of the transaction, the senior vice president directly owned 84,782 shares in the company, valued at $6,485,823. This trade represents a 2.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 27,860 shares of company stock valued at $2,111,581 over the last three months. 8.10% of the stock is owned by corporate insiders.

More ANI Pharmaceuticals News

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI Pharmaceuticals beat Wall Street expectations on both earnings and revenue, reporting $2.05 EPS versus $1.28 expected and revenue of $237.46 million versus $207.63 million expected. The company also said quarterly revenue rose 20.5% year over year, signaling solid underlying growth. Article Title
• Positive Sentiment: The company raised its FY 2026 EPS guidance to $9.19-$9.69, above the consensus estimate of $8.79, which suggests management sees stronger profitability ahead. Article Title
• Neutral Sentiment: Investors are also parsing the earnings call transcript and presentation for details on the company’s growth drivers and updated strategy, but the main stock catalyst today is the beat-and-raise quarter. Article Title
• Neutral Sentiment: ANI also issued revenue guidance around $1.1 billion for FY 2026, roughly in line with expectations, so the revenue outlook appears stable rather than a fresh upside surprise. Article Title

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. ExodusPoint Capital Management LP bought a new stake in shares of ANI Pharmaceuticals during the fourth quarter worth $243,000. Rafferty Asset Management LLC grew its stake in shares of ANI Pharmaceuticals by 28.5% during the fourth quarter. Rafferty Asset Management LLC now owns 2,851 shares of the specialty pharmaceutical company’s stock worth $225,000 after buying an additional 632 shares during the last quarter. Marex Group plc bought a new stake in shares of ANI Pharmaceuticals during the fourth quarter worth $258,000. Inceptionr LLC bought a new stake in shares of ANI Pharmaceuticals during the fourth quarter worth $248,000. Finally, Cerity Partners LLC bought a new stake in shares of ANI Pharmaceuticals during the fourth quarter worth $316,000. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.